States Can't Duck Regeneron Counterclaims In FCA Case
By Julie Manganis · March 3, 2026, 4:04 PM EST
Eleven states pursuing a False Claims Act case against Regeneron Pharmaceuticals over what they say were inflated reimbursements for an eye drug can't block counterclaims by the drugmaker on sovereign immunity...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login